title: Retinoic acid inhibits the growth of human myeloma cells in vitro.
abstract: Retinoic acid has been shown to induce growth inhibition in a variety of cell types including human myeloma cell lines. Bone marrow plasma cells from 31 multiple myeloma (MM) patients were cultured to investigate the activity of 13-cis-retinoic acid (cRA), all-trans-retinoic acid (tRA), interferon-alpha (IFN-alpha), interferon-gamma (IFN-gamma), and dexamethasone (DEX), alone or in combination, on in vitro proliferation and immunoglobulin (Ig) secretion. Both cRA and tRA inhibited proliferation: the labelling index (LI) of treated cultures/controls, was 0.47 +/- 0.05 (mean +/- standard error mean, M +/- SEM) P < 0.0001, and 0.67 +/- 0.04 (M +/- SEM), P < 0.0001, respectively. The inhibitory effect of cRA was significantly superior to tRA (P = 0.0129) and IFN-alpha, similar to IFN-gamma and DEX. The combinations of cRA + IFN alpha, tRA + IFN-gamma, tRA + DEX did not show any synergistic effect on myeloma proliferation. In contrast, the combination cRA + DEX (0.29 +/- 0.04, M +/- SEM) markedly increased the effect of both cRA and DEX used as single agents. Ig synthesis was not significantly affected by CRA, tRA, IFN-gamma and the combination tRA + IFN-gamma. As expected, only IFN-alpha (P = 0.002) and DEX (P < 0.001) inhibited Ig production. The combinations cRA + IFN-alpha, cRA + DEX and tRA + DEX decreased Ig secretion to the same extent as IFN-alpha and DEX alone respectively. In conclusion, our data indicate that tRA and especially cRA strongly inhibited plasma cell proliferation but had no effect on Ig synthesis. The combination of cRA + DEX showed the highest degree of inhibitory activity of all cytokines, alone or in combination.
authors.affiliation: Dipartimento di Medicina ed Oncologia Sperimentale, Universita' di Torino, Ospedale Molinette, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Palumbo
authors.forename: S
authors.initials: S
authors.lastname: Battaglio
authors.forename: P
authors.initials: P
authors.lastname: Napoli
authors.forename: B
authors.initials: B
authors.lastname: Bruno
authors.forename: P
authors.initials: P
authors.lastname: Omedè
authors.forename: M
authors.initials: M
authors.lastname: Boccadoro
authors.forename: A
authors.initials: A
authors.lastname: Pileri
mesh_terms: D000912:Antibodies, Neoplasm / Q000096:biosynthesis; D001973:Bromodeoxyuridine; D002455:Cell Division / Q000187:drug effects; D003907:Dexamethasone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis; D007370:Interferon Type I / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology; D015474:Isotretinoin / Q000494:pharmacology*; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology*; D011994:Recombinant Proteins; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000912:Antibodies, Neoplasm; D007136:Immunoglobulins; D007370:Interferon Type I; D011994:Recombinant Proteins; D014212:Tretinoin; D003907:Dexamethasone; D007371:Interferon-gamma; D015474:Isotretinoin; D001973:Bromodeoxyuridine